|
|
|
|
Notable Labs Ltd (NASDAQ: NTBL) |
|
Price: $0.2479
$-0.09 
-27.684%
|
| Day's High:
| $0.3055
| Week Perf:
| 2.44 %
|
| Day's Low: |
$ 0.24 |
30 Day Perf: |
-44.8 % |
| Volume (M): |
2,111 |
52 Wk High: |
$ 1.16 |
| Volume (M$): |
$ 523 |
52 Wk Avg: |
$0.60 |
| Open: |
$0.30 |
52 Wk Low: |
$0.22 |
|
|
| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
9 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-24 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Notable Labs Ltd
Company Address: 320 Hatch Drive Foster City 94404 CA
Company Phone Number: 851-2410 Stock Exchange / Ticker: NASDAQ NTBL
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Changes
Published Mon, Aug 26 2024 8:06 PM UTC
In a recent announcement, Notable Labs Ltd, a pioneering biotech company focused on personalized cancer therapy, disclosed a change in its leadership as Thomas Bock, MD, stepped down as CEO. Joseph Wagner, PhD, the company s Chief Scientific Officer (CSO), has been appointed as the interim CEO. This change comes at a crucial time for Notable Labs as it has reported...
|
| Notable Labs Ltd
As the Chief Financial Officer of Notable Labs Ltd, I am deeply committed to providing transparency and insight into our financial performance. The recent fiscal period has presented us with both challenges and opportunities as we continue to advance precision medicine in cancer treatment.
Notable Labs Ltd revealed $0.001 million in revenue for the most recent fiscal period, which may appear modest on the surface. However, it is important to note that our focus remains on research and development to bring innovative therapies to market, rather than solely on immediate revenue generation. The net loss of $-3.766 million in the most recent period reflects our ongoing investment in cutting-edge technologies and clinical trials to drive future growth and success.
|
| Clinical Study
Published Thu, Feb 22 2024 1:00 PM UTC
Advancing Precision Medicine in Cancer Treatment: The Role of Volasertib in Relapsed/Refractory Acute Myelogenous LeukemiaPrecision medicine has emerged as a promising approach in cancer treatment, aiming to deliver personalized therapies based on individual patient characteristics. Notable Labs, Ltd., a clinical-stage therapeutics company, is at the forefront of this revolu...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.49 $ |
| Revenues (TTM) |
0.03 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.43 $
|
| Book Value |
0.76 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.49 $
|
| Revenues (TTM) |
0.03 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.43 $
|
| Book Value |
0.76 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
